SeeThruEquity Issues Company Update on OxySure Systems, Inc. (OTCQB: OXYS), Highlighting 3Q15 Results

NEW YORK, NY / ACCESSWIRE / November 25, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update on OxySure Systems, Inc. (OTCQB: OXYS).

The note is available here: OXYS Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

OxySure Systems, Inc. (OTCQB: OXYS, "OxySure") provides innovative short duration / emergency medical oxygen and respiratory solutions for mass market use. Using patented technology that combines two dry, inert powders to create medical oxygen, the Frisco, Texas-based company manufactures and markets the OxySure Model 615, a portable emergency oxygen system that has been approved by the FDA for sale over the counter without a prescription. OxySure has been accelerating its penetration in the marketplace, reporting fourteen consecutive quarters of top line growth, including record revenues in 3Q15. We see several catalysts ahead for the company as it heads in to 2016E seeking to uplist to a national exchange and aspiring to reach $10mn in annualized sales and cash flow breakeven.

Additional highlights of the note are as follows:

High growth continues in 3Q15

OxySure reported its 14th consecutive quarter of growth in 3Q15, with revenue growing a remarkable 39.1% YoY to reach $1,138,380, versus $818,456. For the first three quarters of the year, revenues rose by 52% to reach $2,809,553, versus $1,852,796 in the first three quarters of 2014. Impressively, revenue also grew by approximately 9% sequentially from 2Q15, setting a new record for quarterly revenues at the company.

Strong outlook for 2016E as Model 615 gains traction

OxySure issued a strong outlook for continued growth in 2016E. Management plans on reaching a $10mn annual run rate by the end of the year -- $2.5mn or more in quarterly revenues - as it appears that the company's flagship OxySure Model 615 continues to gain traction in the market. OXYS recently added new territory sales managers in Indiana and Colorado, which should help the company's efforts in its drive towards $10mn in annualized sales. On its 3Q15 earnings call, OxySure management noted that OXYS was approaching $5mn in annualized revenues in 3Q15 ($4.6mn), and states that OxySure was "on track" to reach a $10mn annualized rate in 2016E. Importantly, OXYS management also said that it was targeting cash flow breakeven by the end of 2016E as well. If OXYS achieves both of these goals in the next 4-5 quarters, reaching cash flow generation and a $10mn annualized run rate, this would be a significant milestone for the company and also prove the powerful underlying earnings leverage inherent in the business.

Pushing towards a national listing

OXYS continues to pursue a national listing such as the NASDAQ or NYSE MKT. The company engaged Donohoe Advisory Associates of Rockville, Maryland to assist in this effort in August, and since that time has appointed two new independent members to OxySure's Scientific Advisory Board. Also, in an attempt to ensure the company meets minimum bid requirements, OxySure's Board of Directors has approved a reverse split in a potential range of 1:2 to 1:100. We would see a listing on a prominent national exchange such as the NASDAQ or NYSE MKT as a major accomplishment for OxySure management. A listing on a national exchange would likely improve the liquidity of OXYS stock as well as raise the company's profile both in its industry and among its growing base of institutional investors.

Price target of $2.30 for OXYS

We continue to view OxySure as an attractive growth company offering an intriguing high risk / high reward trade-off in the medical device space. The company's innovative medical device utilizing "oxygen from powder" demonstrated strong growth thus far, with 14 consecutive quarters of growth. If achieved, the $2.30 price target would suggest 820% upside potential

Please review important disclosures on the company's website at www.seethruequity.com.

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity